PEGPH20: Interim Phase II data

Interim data from 146 patients with stage IV metastatic pancreatic cancer who were enrolled in the open-label Phase II Study 202 by April 2014 -- when FDA placed the trial on clinical hold -- showed that PEGPH20 plus Abraxane nab-paclitaxel and gemcitabine led to a median PFS of 9.2 months and an ORR of 71% in patients with high hyaluronan accumulation vs. a median PFS of 4.3 months and an ORR of 29% for Abraxane and gemcitabine. In patients with low hyaluronan accumulation, PEGPH20 plus Abraxane and gemcitabine led to a median PFS of 4.8 months and an ORR of 50% vs. a median PFS of 5.6 months and an ORR of 50% for Abraxane and gemcitabine. ...